Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 162, Issue 6, 2013, Pages 487-520

  Fabbri, Chiara ^a   Di Girolamo, Giulia ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressants; Gene; Major depression; Pharmacogenetics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; DOPAMINE TRANSPORTER; MIRTAZAPINE; PAROXETINE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN HYDROXYLASE;

COST EFFECTIVENESS ANALYSIS; EPIGENETICS; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MONOAMINE METABOLISM; MONOAMINERGIC SYSTEM; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TRANSCRIPTOMICS;

ANTIDEPRESSANTS; GENE; MAJOR DEPRESSION; PHARMACOGENETICS;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PHARMACOGENETICS; PROGNOSIS;

EID: 84881546858     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32184     Document Type: Review

References (352)

1. Adkins DE, Clark SL, Aberg K, Hettema JM, Bukszar J, McClay JL, Souza RP, van den Oord EJ. 2012. Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Transl Psychiatry 2:e129.
2. Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M. 2007. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry 62:1295-1302.
3. Alexopoulos GS, Glatt CE, Hoptman MJ, Kanellopoulos D, Murphy CF, Kelly RE Jr, Morimoto SS, Lim KO, Gunning FM. 2010. BDNF Val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord 125:262-268.
4. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lepine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martinez-Alonso M, Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacin C, Romera B, Taub N, Vollebergh WA. 2004. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 109:21-27.
5. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 2003. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 23:563-567.
6. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 2005. Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol 19:166-172.
7. Arias B, Serretti A, Lorenzi C, Gasto C, Catalan R, Fananas L. 2006. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 90:251-256.
8. Arias B, Serretti A, Mandelli L, Gasto C, Catalan R, Ronchi DD, Fananas L. 2009. Dysbindin gene (DTNBP1) in major depression: Association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenet Genomics 19:121-128.
9. Arias B, Fabbri C, Gressier F, Serretti A, Mitjans M, Gasto C, Catalan R, De Ronchi D, Fananas L. 2013. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: Possible effect in melancholic and psychotic depression. Neuropsychobiology 67:41-47.
10. Azmitia EC Jr, McEwen BS. 1976. Early response of rat brain tryptophan hydroxylase activity to cycloheximide, puromycin and corticosterone. J Neurochem 27:773-778.
11. Baffa A, Hohoff C, Baune BT, Muller-Tidow C, Tidow N, Freitag C, Zwanzger P, Deckert J, Arolt V, Domschke K. 2010. Norepinephrine and serotonin transporter genes: Impact on treatment response in depression. Neuropsychobiology 62:121-131.
12. Bath KG, Jing DQ, Dincheva I, Neeb CC, Pattwell SS, Chao MV, Lee FS, Ninan I. 2012. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 37:1297-1304.
13. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. 2010. miR-16 targets the serotonin transporter: A new facet for adaptive responses to antidepressants. Science 329:1537-1541.
14. Baune BT, Hohoff C, Berger K, Neumann A, Mortensen S, Roehrs T, Deckert J, Arolt V, Domschke K. 2008a. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 33:924-932.
15. Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K. 2008b. Serotonin receptor 1A -1019C/G variant: Impact on antidepressant pharmacoresponse in melancholic depression? Neurosci Lett 436:111-115.
16. Baune BT, Dannlowski U, Domschke K, Janssen DG, Jordan MA, Ohrmann P, Bauer J, Biros E, Arolt V, Kugel H, Baxter AG, Suslow T. 2010. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 67:543-549.
17. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR, Caron MG. 2008. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105:1333-1338.
18. Beaulieu JM, Gainetdinov RR, Caron MG. 2009. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327-347.
19. Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E. 2009. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 203:155-160.
20. Benedetti F, Dallaspezia S, Colombo C, Lorenzi C, Pirovano A, Smeraldi E. 2010. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry 25:476-478.
21. Benedetti F, Dallaspezia S, Lorenzi C, Pirovano A, Radaelli D, Locatelli C, Poletti S, Colombo C, Smeraldi E. 2012. Gene-gene interaction of glycogen synthase kinase 3-beta and serotonin transporter on human antidepressant response to sleep deprivation. J Affect Disord 136:514-519.
22. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Kunzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Kohnlein O, Dabitz H, Bruckl T, Muller N, Pfister H, Lieb R, Mueller JC, Lohmussaar E, Strom TM, Bettecken T, Meitinger T, Uhr M, Rein T, Holsboer F, Muller-Myhsok B. 2004. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36:1319-1325.
23. Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB. 2010. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 67:369-379.
24. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. 2006. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 31:2281-2288.
25. Bishop JR, Ellingrod VL, Akroush M, Moline J. 2009. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: Possible relationship to oral contraceptives. Hum Psychopharmacol 24:207-215.
26. Bortolozzi A, Castane A, Semakova J, Santana N, Alvarado G, Cortes R, Ferres-Coy A, Fernandez G, Carmona MC, Toth M, Perales JC, Montefeltro A, Artigas F. 2012. Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. Mol Psychiatry 17:612-623.
27. Bozina N, Peles AM, Sagud M, Bilusic H, Jakovljevic M. 2008. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry 9:190-197.
28. Brent D, Melhem N, Ferrell R, Emslie G, Wagner KD, Ryan N, Vitiello B, Birmaher B, Mayes T, Zelazny J, Onorato M, Devlin B, Clarke G, DeBar L, Keller M. 2010. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 167:190-197.
29. Breuer ME, Groenink L, Oosting RS, Buerger E, Korte M, Ferger B, Olivier B. 2009. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur J Pharmacol 616:134-140.
30. Broer L, Lill CM, Schuur M, Amin N, Roehr JT, Bertram L, Ioannidis JP, van Duijn CM. 2013. Distinguishing true from false positives in genomic studies: P values. Eur J Epidemiol 28:131-138.
31. Brouwer JP, Appelhof BC, van Rossum EF, Koper JW, Fliers E, Huyser J, Schene AH, Tijssen JG, Van Dyck R, Lamberts SW, Wiersinga WM, Hoogendijk WJ. 2006. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 31:1154-1163.
32. Buist-Bouwman MA, De Graaf R, Vollebergh WA, Alonso J, Bruffaerts R, Ormel J. 2006. Functional disability of mental disorders and comparison with physical disorders: A study among the general population of six European countries. Acta Psychiatr Scand 113:492-500.
33. Bukh JD, Bock C, Vinberg M, Werge T, Gether U, Vedel Kessing L. 2009. Interaction between genetic polymorphisms and stressful life events in first episode depression. J Affect Disord 119:107-115.
34. Catches JS, Xu J, Contractor A. 2012. Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice. Behav Brain Res 228:406-414.
35. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM. 2013. Candidate genes expression profile associated with antidepressants response in the GENDEP study: Differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 38:377-385.
36. Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteux G. 2003. Polymorphisms in the CYP 2D6 gene: Association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 25:738-742.
37. Chen G, Hasanat KA, Bebchuk JM, Moore GJ, Glitz D, Manji HK. 1999. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med 61:599-617.
38. Chi MH, Chang HH, Lee SY, Lee IH, Gean PW, Yang YK, Lu RB, Chen PS. 2010. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord 126:430-435.
39. Choi M, Kang R, Ham B, Jeong H, Lee M. 2005. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 52:155-162.
40. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. 2006. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118:176-182.
41. Ciudad A, Alvarez E, Roca M, Baca E, Caballero L, Garcia de Polavieja P, Casillas M, Valladares A, Gilaberte I. 2012. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: A prospective, longitudinal, observational study. J Clin Psychiatry 73:185-191.
42. Clark SL, Adkins DE, Aberg K, Hettema JM, McClay JL, Souza RP, van den Oord EJ. 2012. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol Med 42:1151-1162.
43. Crisafulli C, Shim DS, Andrisano C, Pae CU, Chiesa A, Han C, Patkar AA, Lee SJ, Serretti A, De Ronchi D. 2012. Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. Psychiatry Res 198:39-46.
44. Crissman AM, Makhay MM, O'Donnell JM. 2001. Discriminative stimulus effects of centrally administered isoproterenol in rats: Mediation by beta-1 adrenergic receptors. Psychopharmacology (Berl) 154:70-75.
45. Crowley JJ, Lipsky RH, Lucki I, Berrettini WH. 2008. Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. Psychiatr Genet 18:248-251.
46. Crumbley C, Wang Y, Kojetin DJ, Burris TP. 2010. Characterization of the core mammalian clock component, NPAS2, as a REV-ERBalpha/RORalpha target gene. J Biol Chem 285:35386-35392.
47. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R, Lorenzi C, Smeraldi E. 2002. Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. Int J Neuropsychopharmacol 5:27-35.
48. Cutler JA, Rush AJ, McMahon FJ, Laje G. 2012. Common genetic variation in the indoleamine-2, 3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J Psychopharmacol 26:360-367.
49. Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 1998. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63:444-452.
50. Dannlowski U, Domschke K, Birosova E, Lawford B, Young R, Voisey J, Morris CP, Suslow T, Konrad C, Kugel H, Ohrmann P, Bauer J, Schoning S, Zavorotnyy M, Diemer J, Arolt V, Baune BT, Zwanzger P. 2011. Dopamine D3 receptor gene variation: Impact on electroconvulsive therapy response and ventral striatum responsiveness in depression. Int J Neuropsychopharmacol 16:1-17.
51. D'Aquila PS, Collu M, Gessa GL, Serra G. 2000. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 405:365-373.
52. de Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, Bruggeman R, Hoogendijk WJ, Penninx BW. 2012. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J.
53. de Vos A, van der Weide J, Loovers HM. 2011. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 11:359-367.
54. Dogan O, Yuksel N, Ergun MA, Yilmaz A, Ilhan MN, Karslioglu HE, Koc A, Menevse A. 2008. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test 12:225-231.
55. Domschke K, Hohoff C, Mortensen LS, Roehrs T, Deckert J, Arolt V, Baune BT. 2008. Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32:224-228.
56. Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P, Deckert J, Arolt V, McMahon FJ, Baune BT. 2010. Brain-derived neurotrophic factor (BDNF) gene: No major impact on antidepressant treatment response. Int J Neuropsychopharmacol 13:93-101.
57. Dong C, Wong ML, Licinio J. 2009. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTR K2: Association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 14:1105-1118.
58. Drago A, Crisafulli C, Sidoti A, Serretti A. 2011. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol 94:418-460.
59. Dreimuller N, Tadic A, Dragicevic A, Boland K, Bondy B, Lieb K, Laux G, Maier W, Muller MJ, Rao ML, Rietschel M, Roschke J, Zill P, Hiemke C. 2011. The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry 45:108-113.
60. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. 2004. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 174:525-529.
61. Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, Baumann P. 2001. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 21:330-334.
62. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, Turgeon J. 2003. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13:39-47.
63. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257-269.
64. EGAP. 2007. Recommendations from the EGAPP Working Group: Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 9:819-825.
65. Ehli EA, Hu Y, Lengyel-Nelson T, Hudziak JJ, Davies GE. 2012. Identification and functional characterization of three novel alleles for the serotonin transporter-linked polymorphic region. Mol Psychiatry 17:185-192.
66. Eichelbaum M, Fromm MF, Schwab M. 2004. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 26:180-185.
67. Fabbri C, Drago A, Serretti A. 2012. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR(*)D. Eur Neuropsychopharmacol 23:612-621.
68. Ferres-Coy A, Pilar-Cuellar F, Vidal R, Paz V, Masana M, Cortes R, Carmona MC, Campa L, Pazos A, Montefeltro A, Valdizan EM, Artigas F, Bortolozzi A. 2013. RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis. Transl Psychiatry 3:e211.
69. Fiskerstrand CE, Lovejoy EA, Quinn JP. 1999. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 458:171-174.
70. Fowler JS, Alia-Klein N, Kriplani A, Logan J, Williams B, Zhu W, Craig IW, Telang F, Goldstein R, Volkow ND, Vaska P, Wang GJ. 2007. Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects. Biol Psychiatry 62:355-358.
71. Franchini L, Serretti A, Gasperini M, Smeraldi E. 1998. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 32:255-259.
72. Fudio S, Borobia AM, Pinana E, Ramirez E, Tabares B, Guerra P, Carcas A, Frias J. 2010. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 626:200-204.
73. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. 2001. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1:152-156.
74. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J. 1999. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47:450-453.
75. Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J. 2000. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 56:175-180.
76. Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG. 1998. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev 26:148-153.
77. Garriock HA, Delgado P, Kling MA, Carpenter LL, Burke M, Burke WJ, Schwartz T, Marangell LB, Husain M, Erickson RP, Moreno FA. 2006. Number of risk genotypes is a risk factor for major depressive disorder: A case control study. Behav Brain Funct 2:24.
78. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP. 2010. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67:133-138.
79. Gendep, Mars, Star D. Investigators. 2013. Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 170:207-217.
80. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G. 2008. CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30:474-482.
81. Gillman PK. 2007. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151:737-748.
82. Govindarajan A, Rao BS, Nair D, Trinh M, Mawjee N, Tonegawa S, Chattarji S. 2006. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci USA 103:13208-13213.
83. Gratacos M, Soria V, Urretavizcaya M, Gonzalez JR, Crespo JM, Bayes M, de Cid R, Menchon JM, Vallejo J, Estivill X. 2008. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J 8:101-112.
84. Gressier F, Bouaziz E, Verstuyft C, Hardy P, Becquemont L, Corruble E. 2009. 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr Genet 19:195-200.
85. Grimes CA, Jope RS. 2001. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391-426.
86. Gudayol-Ferre E, Herrera-Guzman I, Camarena B, Cortes-Penagos C, Herrera-Abarca JE, Martinez-Medina P, Cruz D, Hernandez S, Genis A, Carrillo-Guerrero MY, Aviles Reyes R, Guardia-Olmos J. 2010. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J Affect Disord 127:343-351.
87. Guze SB, Robins E. 1970. Suicide and primary affective disorders. Br J Psychiatry 117:437-438.
88. Haenisch B, Bonisch H. 2011. Depression and antidepressants: Insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 129:352-368.
89. Ham B, Lee M, Lee H, Kang R, Han C, Choi M, Lee S, Ryu S. 2005. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet 15:229-301.
90. Ham BJ, Lee BC, Paik JW, Kang RH, Choi MJ, Choi IG, Lee MS. 2007. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 31:104-107.
91. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, Lesch P. 1996. Allelic variation of human serotonin trasporter gene expression. J Neurochem 66:2621-2624.
92. Higuchi H, Takahashi H, Kamata M, Yoshida K. 2009. Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression. Neuropsychiatr Dis Treat 5:393-398.
93. Holmans P. 2010. Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits. Adv Genet 72:141-179.
94. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
95. Hong CJ, Chen TJ, Yu YW, Tsai SJ. 2006. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 6:27-33.
96. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Muller-Myhsok B, Holsboer F, Binder EB. 2010. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35:727-740.
97. Hougardy DM, Egberts TC, van der Graaf F, Brenninkmeijer VJ, Derijks LJ. 2008. Serotonin transporter polymorphism and bleeding time during SSRI therapy. Br J Clin Pharmacol 65:761-766.
98. Hranilovic D, Stefulj J, Schwab S, Borrmann-Hassenbach M, Albus M, Jernej B, Wildenauer D. 2004. Serotonin transporter promoter and intron 2 polymorphisms: Relationship between allelic variants and gene expression. Biol Psychiatry 55:1090-1094.
99. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D. 2006. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78:815-826.
100. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G, Paddock S, McMahon FJ, Manji H, Lipsky RH. 2007. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 64:783-792.
101. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, Mors O, Maier W, Hauser J, Souery D, Placentino A, Zobel A, Larsen ER, Czerski PM, Gupta B, Hoda F, Perroud N, Farmer A, Craig I, Aitchison KJ, McGuffin P. 2009. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 195:30-38.
102. Hunter AM, Cook IA, Leuchter AF. 2012. Does prior antidepressant treatment of major depression impact brain function during current treatment? Eur Neuropsychopharmacol 22:711-720.
103. Hunter AM, Leuchter AF, Power RA, Muthen B, McGrath PJ, Lewis CM, Cook IA, Garriock HA, McGuffin P, Uher R, Hamilton SP. 2013. A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res.
104. Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, Nakataki M, Song H, Hokoishi K, Tanabe H, Sano A, Ohmori T. 2007. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:658-663.
105. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, Lehtimaki T, Leinonen E, Kampman O. 2009. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 20:1125-1128.
106. Illi A, Poutanen O, Setala-Soikkeli E, Kampman O, Viikki M, Huhtala H, Mononen N, Haraldsson S, Koivisto PA, Leinonen E, Lehtimaki T. 2010a. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? Eur Arch Psychiatry Clin Neurosci 261:95-102.
107. Illi A, Setala-Soikkeli E, Kampman O, Viikki M, Nuolivirta T, Poutanen O, Huhtala H, Mononen N, Lehtimaki T, Leinonen E. 2010b. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Res 176:85-87.
108. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Muller-Myhsok B. 2009. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66:966-975.
109. Ito K, Yoshida K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K. 2002. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 111:235-239.
110. Janssen DG, Caniato RN, Verster JC, Baune BT. 2010. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 25:201-215.
111. Ji Y, Biernacka J, Snyder K, Drews M, Pelleymounter LL, Colby C, Wang L, Mrazek DA, Weinshilboum RM. 2012. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J 12:78-85.
112. Jia P, Wang L, Meltzer HY, Zhao Z. 2011. Pathway-based analysis of GWAS datasets: Effective but caution required. Int J Neuropsychopharmacol 14:567-572.
113. Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, Muller DJ, Kennedy JL, Forgione RN, Kirshner M, Kepple G, Fagiolini A, Kupfer DJ, Bies RR. 2010. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 50:62-72.
114. Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, Owen MJ, Sedvall GC. 1997. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: Relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci 247:297-302.
115. Jonsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC. 2000. A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 34:239-244.
116. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA. 2003. Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 6:339-346.
117. Kang R-H, Wong M-L, Choi M-J, Paik J-W, Lee M-S. 2007a. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:1317-1321.
118. Kang RH, Choi MJ, Paik JW, Hahn SW, Lee MS. 2007b. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatry Med 37:315-329.
119. Kang RH, Hahn SW, Choi MJ, Lee MS. 2007c. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology 56:1-5.
120. Kang R, Chang H, Wong M, Choi M, Park J, Lee H, Jung I, Joe S, Kim L, Kim S, Kim Y, Han C, Ham B, Lee H, Ko Y, Lee M, Lee M. 2009. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol 24:1755-1763.
121. Kato M, Serretti A. 2010. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473-500.
122. Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, Fukuda K, Azuma J, Kinoshita T. 2005. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 20:151-156.
123. Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, Yamashita M, Takekita Y, Nobuhara K, Azuma J, Kinoshita T. 2006. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53:186-195.
124. Kato M, Wakeno M, Okugawa G, Fukuda T, Azuma J, Kinoshita T, Serretti A. 2007. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 56:167-171.
125. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T. 2008a. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32:398-404.
126. Kato M, Wakeno M, Okugawa G, Fukuda T, Takekita Y, Hosoi Y, Azuma J, Kinoshita T, Serretti A. 2008b. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 32:1041-1044.
127. Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamashita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A. 2009a. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet Part B 150B:115-123.
128. Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serretti A. 2009b. 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry Res 167:97-105.
129. Keers R, Aitchison KJ. 2010. Gender differences in antidepressant drug response. Int Rev Psychiatry 22:485-500.
130. Keers R, Bonvicini C, Scassellati C, Uher R, Placentino A, Giovannini C, Rietschel M, Henigsberg N, Kozel D, Mors O, Maier W, Hauser J, Souery D, Mendlewicz J, Schmal C, Zobel A, Larsen ER, Szczepankiewicz A, Kovacic Z, Elkin A, Craig I, McGuffin P, Farmer AE, Aitchison KJ, Gennarelli M. 2010. Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol 25:867-874.
131. Kehne JH. 2007. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 6:163-182.
132. Kim CH, Kim HS, Cubells JF, Kim KS. 1999. A previously undescribed intron and extensive 5′ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem 274:6507-6518.
133. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ. 2000. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215-219.
134. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK. 2006. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 296:1609-1618.
135. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J. 2001. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104:173-192.
136. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J. 2006. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J 7:48-55.
137. Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, Brockmoller J. 2008. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9:841-846.
138. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Naitoh H, Nakamura J, Ozaki N, Iwata N. 2009. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromol Med 12:237-242.
139. Kishi T, Fukuo Y, Yoshimura R, Okochi T, Kitajima T, Naitoh H, Umene-Nakano W, Nakamura J, Ozaki N, Iwata N. 2010. Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population. Hum Psychopharmacol 25:481-486.
140. Kocabas NA, Faghel C, Barreto M, Kasper S, Linotte S, Mendlewicz J, Noro M, Oswald P, Souery D, Zohar J, Massat I. 2010. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: A case-control association study. Int Clin Psychopharmacol 25:218-227.
141. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, Linotte S, Massat I, Mendlewicz J, Noro M, Montgomery S, Oswald P, Snyder L, Zohar J, Souery D. 2011a. Brain-derived neurotrophic factor gene polymorphisms: Influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 26:1-10.
142. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, Linotte S, Massat I, Montgomery S, Noro M, Oswald P, Snyder L, Souery D, Zohar J, Mendlewicz J. 2011b. Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes. World J Biol Psychiatry 11:985-990.
143. Kraft J, Slager S, McGrath P, Hamilton S. 2005. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 58.
144. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP. 2007. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 61:734-742.
145. Krishnadas R, Cavanagh J. 2012. Depression: An inflammatory illness? J Neurol Neurosurg Psychiatry 83:495-502.
146. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. 2002. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7(Suppl. 1):S71-S80.
147. Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, Hirose T, Nanko S. 1997. Serotonin transporter gene polymorphisms: Ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 2:457-462.
148. Kvist EE, Al-Shurbaji A, Dahl ML, Nordin C, Alvan G, Stahle L. 2001. Quantitative pharmacogenetics of nortriptyline: A novel approach. Clin Pharmacokinet 40:869-877.
149. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, Buchanan DD, Silburn PA, Halliday GM, Schofield PR. 2005. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 58:829-839.
150. Laika B, Leucht S, Steimer W. 2006. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): Lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem 52:893-895.
151. Laje G, McMahon FJ. 2010. Genome-wide association studies of antidepressant outcome: A brief review. Prog Neuropsychopharmacol Biol Psychiatry 35:1553-1557.
152. Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ. 2007. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 164:1530-1538.
153. Lavretsky H, Siddarth P, Kumar A, Reynolds CF III. 2008. The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: A pilot study. Int J Geriatr Psychiatry 23:55-59.
154. Lee HJ, Cha JH, Ham BJ, Han CS, Kim YK, Lee SH, Ryu SH, Kang RH, Choi MJ, Lee MS. 2004a. Association between a G-protein beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J 4:29-33.
155. Lee MS, Lee HY, Lee HJ, Ryu SH. 2004b. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet 14:111-115.
156. Lee SH, Lee KJ, Lee HJ, Ham BJ, Ryu SH, Lee MS. 2005. Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder. Psychiatry Clin Neurosci 59:140-145.
157. Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW. 2006. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 28:382-387.
158. Lee HY, Kang RH, Paik JW, Jeong YJ, Chang HS, Han SW, Lee MS. 2009. Association of the adrenergic alpha 2a receptor-1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Brain Res 1262:1-6.
159. Lee SH, Choi TK, Lee E, Seok JH, Lee SH, Lee HS, Kim SJ. 2010. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology 62:198-206.
160. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ, Paddock S. 2008. The FKBP5-gene in depression and treatment response-An association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 63:1103-1110.
161. Lemonde S, Turecki G, Bakish D, Du L, Hrdina P, Bown C, Sequeira A, Kushwaha N, Morris S, Basak A, Ou X, Albert P. 2003. Impaired trans-repression at a 5-HT1A receptor gene polimorphism associated with major depression and suicide. J Neurosci 23:8788-8799.
162. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. 2004. Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 7:501-506.
163. Levin GM, Bowles TM, Ehret MJ, Langaee T, Tan JY, Johnson JA, Millard WJ. 2007. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 11:155-160.
164. Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, Grozeva D, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Peters TJ. 2011. Polymorphism of the 5-HT transporter and response to antidepressants: Randomised controlled trial. Br J Psychiatry 198:464-471.
165. Licinio J, O'Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, Lake S, Tantisira K, Weiss S, Wong M. 2004. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 9:1075-1082.
166. Licinio J, Dong C, Wong ML. 2009. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 66:488-497.
167. Lifschytz T, Gur E, Lerer B, Newman ME. 2004. Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: Regional differences. J Neurosci Methods 140:133-139.
168. Lin WY, Lee WC. 2012. Improving power of genome-wide association studies with weighted false discovery rate control and prioritized subset analysis. PLoS ONE 7:e33716.
169. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. 2007. No gene is an island: The flip-flop phenomenon. Am J Hum Genet 80:531-538.
170. Lin E, Chen PS, Chang HH, Gean PW, Tsai HC, Yang YK, Lu RB. 2009. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 33:1167-1172.
171. Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, Wang H, Liu H, Wang X, Wu Y, Cao Z, Li W. 2007. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 414:155-158.
172. LLerena A, Dorado P, Berecz R, Gonzalez AP, Penas LEM. 2004. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 59:869-873.
173. Lotrich FE, Pollock BG, Kirshner M, Ferrell RF, Reynolds CF III. 2008. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 33:123-130.
174. Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Muller-Myhsok B, Holsboer F, Domschke K. 2010. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 20:65-68.
175. MacKenzie A, Quinn J. 1999. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 96:15251-15255.
176. Maron E, Tammiste A, Kallassalu K, Eller T, Vasar V, Nutt DJ, Metspalu A. 2009. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol 19:451-456.
177. McEwen BS, Conrad CD, Kuroda Y, Frankfurt M, Magarinos AM, McKittrick C. 1997. Prevention of stress-induced morphological and cognitive consequences. Eur Neuropsychopharmacol 7(Suppl. 3):S323-S328.
178. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H. 2006. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804-814.
179. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH. 2001. The effect of paroxetine on 5-HT2A receptors in depression: An [18F]setoperone PET imaging study. Am J Psychiatry 158:78-85.
180. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M. 2008. MDR1 gene polymorphism: Therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32:1439-1444.
181. Miller AH, Maletic V, Raison CL. 2009. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732-741.
182. Min W, Li T, Ma X, Li Z, Yu T, Gao D, Zhang B, Yun Y, Sun X. 2009. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) 205:409-417.
183. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, Rupprecht R, Bondy B. 2001. Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression. Neurosci Lett 303:119-122.
184. Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D. 2011. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 12:171-184.
185. Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. 2000. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol 20:141-149.
186. Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA, Black JL III, Weinshilboum RM. 2009. SLC6A4 variation and citalopram response. Am J Med Genet Part B 150B:341-351.
187. Muller DJ, Schulze TG, Macciardi F, Ohlraun S, Gross MM, Scherk H, Neidt H, Syagailo YV, Grassle M, Nothen MM, Maier W, Lesch KP, Rietschel M. 2002. Moclobemide response in depressed patients: Association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry 35:157-158.
188. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. 2003. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160:1830-1835.
189. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. 2004. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 61:1163-1169.
190. Musil R, Zill P, Seemuller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Moller HJ, Riedel M. 2012. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. Eur Arch Psychiatry Clin Neurosci.
191. Myung W, Lim SW, Kim S, Kim H, Chung JW, Seo MY, Kim JW, Carroll BJ, Kim DK. 2013. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology (Berl) 225:283-290.
192. Ng CH, Easteal S, Tan S, Schweitzer I, Ho BK, Aziz S. 2006. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry 30:953-957.
193. Nichols AI, Lobello K, Guico-Pabia CJ, Paul J, Preskorn SH. 2009. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status. J Clin Psychopharmacol 29:383-386.
194. Nikisch G, Eap CB, Baumann P. 2008. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. Pharmacol Res 58:344-347.
195. Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, Linotte S, Mendlewicz J, Montgomery S, Snyder L, Souery D, Verbanck P, Zohar J, Massat I. 2010. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol 25:228-231.
196. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, Papakostas GI, Souery D, Trivedi MH, Tylee A. 2006. Consensus statement and research ne eds the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 67(Suppl 6):46-49.
197. Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, Carrasco JL, Stahl S. 2007. The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. J Psychopharmacol 21:461-471.
198. Olgiati P, Bajo E, Bigelli M, De Ronchi D, Serretti A. 2012. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry 36:147-154.
199. Overstreet D, Griebel G. 2004. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 497:49-53.
200. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ. 2007. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 164:1181-1188.
201. Pae CU, Serretti A, Mandelli L, De Ronchi D, Patkar AA, Jun TY, Kim JJ, Lee CU, Lee SJ, Lee C, Paik IH. 2007. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenet Genomics 17:69-75.
202. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734.
203. Pandey DK, Mahesh R, Kumar AA, Rao VS, Arjun M, Rajkumar R. 2010. A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: Approaching early-onset antidepressants. Pharmacol Biochem Behav 94:363-373.
204. Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. 2007. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 104:83-90.
205. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. 2006. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: Preliminary data from a naturalistic study. Neuropsychopharmacology 31:1745-1749.
206. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. 1997. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:1594-1597.
207. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M. 2003. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 54:879-883.
208. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. 2009a. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 65:785-791.
209. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, McMahon FJ. 2009b. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 34:1819-1828.
210. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. 2010. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 67:1110-1113.
211. Perlis RH, Fijal B, Dharia S, Houston JP. 2012. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J 13:280-285.
212. Perroud N, Salzmann A, Saiz PA, Baca-Garcia E, Sarchiapone M, Garcia-Portilla MP, Carli V, Vaquero-Lorenzo C, Jaussent I, Mouthon D, Vessaz M, Huguelet P, Courtet P, Malafosse A. 2010. Rare genotype combination of the serotonin transporter gene associated with treatment response in severe personality disorder. Am J Med Genet Part B 153B:1494-1497.
213. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. 2004. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 9:879-889.
214. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP. 2008. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE 3:e1872.
215. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, Kraft JB, McGrath PJ, Hamilton SP. 2009. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 19:1-10.
216. Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, Waggoner SG, Tahl AR, Sklar P. 2010. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 15:810-815.
217. Pickard BS, Malloy MP, Christoforou A, Thomson PA, Evans KL, Morris SW, Hampson M, Porteous DJ, Blackwood DH, Muir WJ. 2006. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 11:847-857.
218. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ. 2000. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590.
219. Popp J, Leucht S, Heres S, Steimer W. 2006. Serotonin transporter polymorphisms and side effects in antidepressant therapy-A pilot study. Pharmacogenomics 7:159-166.
220. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. 2011a. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 36:87-113.
221. Porcelli S, Fabbri C, Spina E, Serretti A, De Ronchi D. 2011b. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol 7:1101-1115.
222. Porcelli S, Fabbri C, Drago A, Gibiino S, De Ronchi D, Serretti A. 2011c. Genetics and antidepressants: Where we are. Clin Neuropsychiatry 7:99-150.
223. Porcelli S, Fabbri C, Serretti A. 2012. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22:239-258.
224. Pratt WB, Morishima Y, Murphy M, Harrell M. 2006. Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol 172:111-138.
225. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-752.
226. Rada JA, Cornuet PK, Hassell JR. 1993. Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins. Exp Eye Res 56:635-648.
227. Rausch JL, Johnson ME, Fei Y-J, Li JQ, Shendarkar N, Mac Hobby H, Ganapathy V, Leibach FH. 2002. Initial conditions of serotonin transporter kinetics and genotype: Influence on ssri treatment trial outcome. Biol Psychiatry 51:723-732.
228. Reimherr F, Amsterdam J, Dunner D, Adler L, Zhang S, Williams D, Marchant B, Michelson D, Nierenberg A, Schatzberg A, Feldman P. 2010. Genetic polymorphisms in the treatment of depression: Speculations from an augmentation study using atomoxetine. Psychiatry Res 175:67-73.
229. Risselada AJ, Mulder H, Heerdink ER, Grube AM, Wilmink FW, Egberts TC. 2010. The association between serotonin 2C receptor polymorphisms and weight gain and eating behavior in patients using mirtazapine: A prospective follow-up study. J Clin Psychopharmacol 30:207-209.
230. Rohde HM, Cheong FY, Konrad G, Paiha K, Mayinger P, Boehmelt G. 2003. The human phosphatidylinositol phosphatase SAC1 interacts with the coatomer I complex. J Biol Chem 278:52689-52699.
231. Rudberg I, Hendset M, Uthus LH, Molden E, Refsum H. 2006. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther Drug Monit 28:102-105.
232. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. 2008. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322-327.
233. Ruhe HG, Ooteman W, Booij J, Michel MC, Moeton M, Baas F, Schene AH. 2009. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics 19:67-76.
234. Ruiz-Velasco V, Ikeda SR. 2003. A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels. Physiol Genomics 13:85-95.
235. Ryan BM, Robles AI, Harris CC. 2010. Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer 10:389-402.
236. Sabol SZ, Hu S, Hamer D. 1998. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103:273-279.
237. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM Jr. 2010a. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 20:467-475.
238. Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM Jr. 2010b. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet Part B 153B:554-560.
239. Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K. 2002. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 46:136-140.
240. Sawamura K, Suzuki Y, Someya T. 2004. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 60:553-557.
241. Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. 2005. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 97:296-301.
242. Secher A, Bukh J, Bock C, Koefoed P, Rasmussen HB, Werge T, Kessing LV, Mellerup E. 2009. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol 24:199-203.
243. Serretti A, Zanardi R, Cusin C, Rossini D, Lilli R, Lorenzi C, Lattuada E, Smeraldi E. 2001a. No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res 104:195-203.
244. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. 2001b. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 11:375-380.
245. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. 2001c. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 6:586-592.
246. Serretti A, Lorenzi C, Cusin C, Zanardi R, Lattuada E, Rossini D, Lilli R, Pirovano A, Catalano M, Smeraldi E. 2003. SSRIs antidepressant activity is influenced by Gbeta3 variants. Eur Neuropsychopharmacol 13:117-122.
247. Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R. 2004a. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: Preliminary findings. Int J Neuropsychopharmacol 7:453-460.
248. Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R. 2004b. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet Part B 129B:36-40.
249. Serretti A, Calati R, Mandelli L, De Ronchi D. 2006. Serotonin transporter gene variants and behavior: A comprehensive review. Curr Drug Targets 7:1659-1669.
250. Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J. 2011a. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 128:56-63.
251. Serretti A, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Pae CU. 2011b. Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Res 189:26-32.
252. Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. 2011c. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 12:501-515.
253. Serretti A, Chiesa A, Crisafulli C, Massat I, Linotte S, Calati R, Kasper S, Bailer U, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J. 2012. Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. Neuropsychobiology 65:70-75.
254. Seymour P, Schmidt A, Schulz D. 2003. The pharmacology of CP-154, 526, a non-peptide antagonist of the CRH1 receptor: A review. CNS Drug Rev 9:57-96.
255. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S. 2006. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:493-502.
256. Shen X, Carlborg O. 2013. Beware of risk for increased false positive rates in genome-wide association studies for phenotypic variability. Front Genet 4:93.
257. Shih JC, Chen K, Ridd MJ. 1999. Monoamine oxidase: From genes to behavior. Annu Rev Neurosci 22:197-217.
258. Shimoda K, Someya T, Yokono A, Morita S, Hirokane G, Takahashi S, Okawa M. 2002. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol 22:371-378.
259. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, Garriock HA, Yokoyama JS, McGrath PJ, Peters EJ, Scheftner WA, Coryell W, Lawson WB, Jancic D, Gejman PV, Sanders AR, Holmans P, Slager SL, Levinson DF, Hamilton SP. 2011. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry 16:202-215.
260. Singh YS, Altieri SC, Gilman TL, Michael HM, Tomlinson ID, Rosenthal SJ, Swain GM, Murphey-Corb MA, Ferrell RE, Andrews AM. 2012. Differential serotonin transport is linked to the rh5-HTTLPR in peripheral blood cells. Transl Psychiatry 2:e77.
261. Skolnick P, Popik P, Trullas R. 2009. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563-569.
262. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M. 1998. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511.
263. Smits K, Smits L, Peeters F, Schouten J, Janssen R, Smeets H, van Os J, Prins M. 2007. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 22:137-143.
264. Smits KM, Smits LJ, Peeters FP, Schouten JS, Janssen RG, Smeets HJ, van Os J, Prins MH. 2008. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 18:184-190.
265. Spronk D, Arns M, Barnett KJ, Cooper NJ, Gordon E. 2011. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: A pilot study. J Affect Disord 128:41-48.
266. Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A, Murphy KC, Jones L, Buckland PR, McGuffin P, Lesch KP, Owen MJ. 1998. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 3:42-49.
267. Stamm TJ, Adli M, Kirchheiner J, Smolka MN, Kaiser R, Tremblay PB, Bauer M. 2008. Serotonin transporter gene and response to lithium augmentation in depression. Psychiatr Genet 18:92-97.
268. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. 2004. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 50:1623-1633.
269. Stein DJ, Daniels WM, Savitz J, Harvey BH. 2008. Brain-derived neurotrophic factor: The neurotrophin hypothesis of psychopathology. CNS Spectr 13:945-949.
270. Strohmaier J, Wust S, Uher R, Henigsberg N, Mors O, Hauser J, Souery D, Zobel A, Dernovsek MZ, Streit F, Schmal C, Kozel D, Placentino A, Farmer A, McGuffin P, Aitchison KJ, Rietschel M. 2011. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 12:528-538.
271. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. 2006. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J 6:351-356.
272. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA. 2003. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111:1843-1851.
273. Suzuki Y, Sawamura K, Someya T. 2004. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacoeconomics J 4:283-286.
274. Suzuki Y, Sawamura K, Someya T. 2006. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 31:825-831.
275. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, Stassen HH, Dahmen N. 2005. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 5:49-53.
276. Tadic A, Muller MJ, Rujescu D, Kohnen R, Stassen HH, Dahmen N, Szegedi A. 2007. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet Part B 144B:325-331.
277. Tadic A, Rujescu D, Muller MJ, Kohnen R, Stassen HH, Szegedi A, Dahmen N. 2008. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat 4:269-276.
278. Takahashi H, Yoshida K, Ito K, Sato K, Kamata M, Higuchi H, Shimizu T, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K. 2002. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 12:477-481.
279. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, Hahn CG, Siegel SJ, Trojanowski JQ, Gur RE, Blake DJ, Arnold SE. 2004. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113:1353-1363.
280. Tanaka M, Kobayashi D, Murakami Y, Ozaki N, Suzuki T, Iwata N, Haraguchi K, Ieiri I, Kinukawa N, Hosoi M, Ohtani H, Sawada Y, Mine K. 2008. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 11:261-267.
281. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D, Hall SK, Hauser J, Henigsberg N, Hu X, Jerman B, Maier W, Mors O, O'Donovan M, Peters TJ, Placentino A, Rietschel M, Souery D, Aitchison KJ, Craig I, Farmer A, Wendland JR, Malafosse A, Holmans P, Lewis G, Lewis CM, Stensbol TB, Kapur S, McGuffin P, Uher R. 2012. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: A genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 9:e1001326.
282. Tansey KE, Guipponi M, Hu X, Domenici E, Lewis G, Malafosse A, Wendland JR, Lewis CM, McGuffin P, Uher R. 2013. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 73:679-682.
283. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. 2006. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: A critical overview. Pharmacol Rev 58:115-134.
284. Taylor MJ, Sen S, Bhagwagar Z. 2010a. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 68:536-543.
285. Taylor WD, McQuoid DR, Ashley-Koch A, Macfall JR, Bridgers J, Krishnan RR, Steffens DC. 2010b. BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J 11:146-154.
286. Terracciano A, Tanaka T, Sutin AR, Sanna S, Deiana B, Lai S, Uda M, Schlessinger D, Abecasis GR, Ferrucci L, Costa PT Jr. 2010. Genome-wide association scan of trait depression. Biol Psychiatry 68:811-817.
287. Trivedi MH, Daly EJ. 2008. Treatment strategies to improve and sustain remission in major depressive disorder. Dialogues Clin Neurosci 10:377-384.
288. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. 2003. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet Part B 123B:19-22.
289. Tsai SJ, Hong CJ, Chen TJ, Yu YW. 2007. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet Part B 144B:1097-1098.
290. Tsai SJ, Hong CJ, Liou YJ. 2008a. Brain-derived neurotrophic factor and antidepressant action: Another piece of evidence from pharmacogenetics. Pharmacogenomics 9:1353-1358.
291. Tsai SJ, Liou YJ, Hong CJ, Yu YW, Chen TJ. 2008b. Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J 8:384-390.
292. Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ. 2009a. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 113:183-187.
293. Tsai SJ, Hong CJ, Liou YJ, Chen TJ, Chen ML, Hou SJ, Yen FC, Yu YW. 2009b. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Res 169:113-117.
294. Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ, Hou SJ, Yen FC. 2009c. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 33:637-641.
295. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL. 2010. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11:537-546.
296. Tzeng DS, Chien CC, Lung FW, Yang CY. 2009. MAOA gene polymorphisms and response to mirtazapine in major depression. Hum Psychopharmacol 24:293-300.
297. Tzvetkov MV, Brockmoller J, Roots I, Kirchheiner J. 2008. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics 18:495-506.
298. Ueda M, Hirokane G, Morita S, Okawa M, Watanabe T, Akiyama K, Shimoda K. 2006. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 30:486-491.
299. Uher R. 2011. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry 19:109-124.
300. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I. 2009. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9:225-233.
301. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P. 2010. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167:555-564.
302. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F. 2008. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57:203-209.
303. Umene-Nakano W, Yoshimura R, Ueda N, Suzuki A, Ikenouchi-Sugita A, Hori H, Otani K, Nakamura J. 2009. Predictive factors for responding to sertraline treatment: Views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol 24:1764-1771.
304. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. 2005. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 27:478-483.
305. van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S, Salyakina D, Lamberts SW, Holsboer F. 2006. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 59:681-688.
306. Vesell ES. 1989. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 41:535-552.
307. Viikki M, Huuhka K, Leinonen E, Illi A, Setala-Soikkeli E, Huuhka M, Mononen N, Lehtimaki T, Kampman O. 2011. Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neurosci Lett 501:20-24.
308. Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M. 2009. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 19:281-291.
309. Wang HC, Yeh TL, Chang HH, Gean PW, Chi MH, Yang YK, Lu RB, Chen PS. 2011. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology (Berl) 213:773-779.
310. Wang Y, Liu X, Yu Y, Han Y, Wei J, Collier D, Li T, Ma X. 2012. The role of single nucleotide polymorphism of D(2) dopamine receptor gene on major depressive disorder and response to antidepressant treatment. Psychiatry Res 200:1047-1050.
311. Warner-Schmidt JL, Duman RS. 2007. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 104:4647-4652.
312. Weinshilboum RM, Otterness DM, Szumlanski CL. 1999. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19-52.
313. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 447:661-678.
314. WHO. 2007. Ten statistical highlights in global public health. World Health Statistics.
315. Whyte EM, Romkes M, Mulsant BH, Kirshne MA, Begley AE, Reynolds CF III, Pollock BG. 2006. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 21:542-549.
316. Wieronska JM, Klak K, Palucha A, Branski P, Pilc A. 2007. Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Res 1184:88-95.
317. Wilkie MJ, Smith D, Reid IC, Day RK, Matthews K, Wolf CR, Blackwood D, Smith G. 2007. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics 17:207-215.
318. Wilkie MJ, Smith G, Day RK, Matthews K, Smith D, Blackwood D, Reid IC, Wolf CR. 2009. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 9:61-70.
319. Willner P. 1983a. Dopamine and depression: A review of recent evidence. I. Empirical studies. Brain Res 287:211-224.
320. Willner P. 1983b. Dopamine and depression: A review of recent evidence. III. The effects of antidepressant treatments. Brain Res 287:237-246.
321. Willner P, Hale AS, Argyropoulos S. 2005. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 86:37-45.
322. Wong ML, Dong C, Maestre-Mesa J, Licinio J. 2008. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 13:800-812.
323. Wu WH, Huo SJ, Cheng CY, Hong CJ, Tsai SJ. 2001. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 44:172-175.
324. Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, Li L. 2011. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord 133:165-173.
325. Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, Li L, Reynolds GP. 2012. Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol 26:349-359.
326. Yang J, Lee SH, Goddard ME, Visscher PM. 2011. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 88:76-82.
327. Yanpallewar SU, Fernandes K, Marathe SV, Vadodaria KC, Jhaveri D, Rommelfanger K, Ladiwala U, Jha S, Muthig V, Hein L, Bartlett P, Weinshenker D, Vaidya VA. 2010. Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J Neurosci 30:1096-1109.
328. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K. 2002a. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 26:383-386.
329. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K. 2002b. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 26:1279-1283.
330. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Suzuki T, Ohkubo T. 2003. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 48:10-13.
331. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB. 2004. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 161:1575-1580.
332. Yoshida K, Higuchi H, Kamata M, Takahashi H, Inoue K, Suzuki T, Itoh K, Ozaki N. 2007. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 21:650-656.
333. Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, Inoue K, Suzuki T, Itoh K, Ozaki N. 2008. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol 23:121-128.
334. Yoshimura R, Umene-Nakano W, Suzuki A, Ueda N, Miyamoto K, Ikenouchi-Sugita A, Hori H, Otani K, Nakamura J. 2009. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol 24:489-494.
335. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. 2002. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7:1115-1119.
336. Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH. 2003a. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 31:1255-1259.
337. Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ. 2003b. Association study of the interleukin-1beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 28:1182-1185.
338. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. 2005. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 30:1719-1723.
339. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ. 2006. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 16:498-503.
340. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E. 2000. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 20:105-107.
341. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E. 2001. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323-330.
342. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
343. Zhang W, Dolan ME. 2009. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des 15:3782-3795.
344. Zhang H, Etherington LA, Hafner AS, Belelli D, Coussen F, Delagrange P, Chaouloff F, Spedding M, Lambert JJ, Choquet D, Groc L. 2012. Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule. Mol Psychiatry 18:471-484.
345. Zhao X, Huang Y, Li J, Ma H, Jin Q, Wang Y, Wu L, Zhu G. 2012. Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: A meta-analysis. Int Clin Psychopharmacol 27:314-320.
346. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, Damschroder-Williams P, Du J, Chen G, Manji HK. 2009. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34:1395-1405.
347. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B. 2000. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 11:1893-1897.
348. Zill P, Baghai TC, Engel R, Zwanzger P, Schule C, Minov C, Behrens S, Bottlender R, Jager M, Rupprecht R, Moller HJ, Ackenheil M, Bondy B. 2003. Beta-1-adrenergic receptor gene in major depression: Influence on antidepressant treatment response. Am J Med Genet Part B 120B:85-89.
349. Zill P, Baghai TC, Engel R, Zwanzger P, Schule C, Eser D, Behrens S, Rupprecht R, Moller HJ, Ackenheil M, Bondy B. 2004a. The dysbindin gene in major depression: An association study. Am J Med Genet Part B 129B:55-58.
350. Zill P, Buttner A, Eisenmenger W, Bondy B, Ackenheil M. 2004b. Regional mRNA expression of a second tryptophan hydroxylase isoform in postmortem tissue samples of two human brains. Eur Neuropsychopharmacol 14:282-284.
351. Zobel A, Schuhmacher A, Jessen F, Hofels S, von Widdern O, Metten M, Pfeiffer U, Hanses C, Becker T, Rietschel M, Scheef L, Block W, Schild HH, Maier W, Schwab SG. 2010. DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int J Neuropsychopharmacol 13:649-660.
352. Zou YF, Wang Y, Liu P, Feng XL, Wang BY, Zang TH, Yu X, Wei J, Liu ZC, Liu Y, Tao M, Li HC, Li KQ, Hu J, Li M, Zhang KR, Ye DQ, Xu XP. 2010. Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Hum Psychopharmacol 25:145-152.